Alvogen Korea

What Alvogen Korea does

Alvogen Korea (알보젠코리아주식회사) is a South Korean specialty pharmaceutical company founded in 2015 and headquartered in Seoul, operating as a wholly-owned subsidiary of Lotus Pharmaceutical. The company markets a diversified portfolio of specialty ethical drugs (ETC) and over-the-counter (OTC) medicines spanning therapeutic areas including oncology, immunology, urology, cardiovascular, central nervous system, musculoskeletal, and obesity. Branded franchises include Mercilon, described as the top-selling oral contraceptive brand in Korea, Senatrip for vaginal infections, and the recently approved immuno-oncology drug Sufrulimab (serplulimab) for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The company also distributes Eurobalsam (유로박솜®) for recurrent urinary tract infections and sells generic products such as Sinasset Tablet (cinacalcet hydrochloride).

The core technology platform is complex generic and specialty pharmaceutical development, with particular depth in oncology and immunology. The company markets products developed jointly with Shanghai Henlius Biotech (Sufrulimab) and leverages the parent Lotus Pharmaceutical group's R&D pipeline of 80+ programs, 250+ commercial products, 100+ global partnerships, and 265+ licensing deals. Alvogen Korea holds Korean regulatory approvals for its ETC portfolio and emphasizes systematic quality control, stable supply, and partnerships with global pharmaceutical companies as elements of its technical capability.

Alvogen Korea generates revenue through pharmaceutical product sales covering both prescription (ETC) and OTC channels, plus licensing and distribution income. Pricing is regulated and not publicly disclosed. The company sells primarily to hospitals, clinics, and pharmacies across South Korea via direct enterprise field sales and an online ordering system for registered medical institutions, while also running consumer-facing campaigns for OTC brands such as Mercilon. The company employs 26 people and is led by Representative Director and President Lee Wook-se (이육세).

Name

Alvogen Korea

Legal name

알보젠코리아주식회사

Website

https://alvogenkorea.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Alvogen Korea is a Seoul-based specialty pharmaceutical subsidiary of Lotus Pharmaceutical that markets branded and generic prescription (ETC) and OTC drugs across oncology, urology, cardiovascular, CNS, obesity, and women's health to Korean hospitals, clinics, pharmacies, and consumers.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Generic Hospital & Institutional Products (HLAIABAL), OTC & Consumer Health Distributors (HLAIAJAC), Oral Solid Dose (OSD) Generics (HLAIABAD)

Keywords

• Specialty pharmaceuticals
• Generic drug distribution
• Prescription medicines
• Oncology therapeutics
• Pharmaceutical manufacturing

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Alvogen Korea generates revenue through the sale of specialty ethical pharmaceuticals (ETC), generic drugs, branded generics, and OTC medicines covering therapeutic areas including obesity, cardiovascular, urology, musculoskeletal, CNS, and oncology. Revenue is derived from both prescription and over-the-counter channels.
2. Licensing and Distribution: The company earns revenue through licensing deals and distribution partnerships, including inbound licensing of products such as 서플루마 (Sufolumab) co-developed with Shanghai Henlius Biotech, and the domestic distribution of products like 유로박솜®.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Alvogen Korea sells specialty ethical pharmaceuticals (ETC) and OTC medicines in South Korea across therapeutic areas including obesity, cardiovascular, urology, musculoskeletal, central nervous system, and oncology/immunology. As a subsidiary of Lotus Pharmaceutical, it leverages a portfolio of 250+ commercial products and an 80+ program R&D pipeline, distributing branded generics such as Mercilon, specialty drugs such as 유로박솜® and 서플루마, and biosimilars through direct sales to healthcare institutions and pharmacies.

Product overview

Alvogen Korea is a pharmaceutical company and subsidiary of Lotus Pharmaceutical (Lotus 그룹), offering a diversified portfolio of prescription (전문의약품/ETC) and OTC (일반의약품) medications. The company focuses on specialty therapeutic areas including obesity treatment, cardiovascular, urology, musculoskeletal, central nervous system, and oncology. Product portfolio includes branded oral contraceptives (머시론/Mercilon), specialty prescription drugs (유로박솜®, 서플루마, 세나트리플), and generic medications. The company also develops oncology and immunology-focused generic pharmaceuticals and biosimilars, supported by a pipeline of 80+ R&D programs and 100+ global partnerships. Alvogen Korea operates an online ordering system for pharmaceutical products.

Differentiator

Problem solved

Functional benefit

Brands

• 머시론 (Mercilon): Alvogen Korea's top-selling oral contraceptive brand for women, marketed with the 2026 campaign tagline '나의 멋을 지키는 이론, 머시론' (Theory of Protecting My Style, Mercilon).
• 서플루마 (Sufrulimab)
• 유로박솜 (Urobosom)
• 세나트리플

Products and services

• Mercilon (머시론)
• 유로박솜® (Urobalsam® / Eurobalsam®)
• Serplulimab (서플루마 / Sufluma) Immuno-oncology drug co-developed with Shanghai Henlius Biotech; received Korean regulatory approval in July 2026 as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) in combination with carboplatin and etoposide, with Phase 3 global trial showing a 4.7-month overall survival extension.
• Senatrip (세나트리플) Women's health product for treatment of vaginitis and vaginal infections, marketed under the 'The World is Simple' (세상심플) campaign positioning.
• Cinacalcet hydrochloride (시나세트정) Generic medication containing cinacalcet hydrochloride, used in renal and related conditions, subject to a recall announcement in February 2026 under Pharmaceutical Affairs Act Article 72.

Quantifiable outcome

• 서플루마 (Sufolumab) demonstrated a 4.7-month extension in overall survival in Phase 3 global trial for extended-stage small cell lung cancer (ES-SCLC) when combined with carboplatin.

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• Shanghai Henlius Biotechnology (상하이 헨리우스 바이오텍)coreStrategic or Co-development Partner · 2 July 2026Alvogen Korea and Shanghai Henlius Biotechnology co-developed the immuno-oncology drug 서플루마 (Sufolumab), which received Korean regulatory approval for use as a first-line treatment for extended-stage small cell lung cancer (ES-SCLC) in combination with carboplatin. The global Phase 3 trial demonstrated a 4.7-month extension in overall survival. Alvogen Korea is responsible for domestic distribution and commercialization in South Korea.
• Lotus Pharmaceutical (Lotus 그룹)coreStrategic or Co-development PartnerAlvogen Korea is a subsidiary of the global pharmaceutical group Lotus Pharmaceutical. The company leverages the group's global network, R&D pipeline of 80+ programs, 250+ commercial products, 100+ global partnerships, and 265+ licensing deals to strengthen its competitive position in the Korean specialty pharmaceutical market.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Ildong Pharmaceutical: Korean pharma company with a portfolio spanning specialty Rx, OTC, and consumer health. Comparable on hybrid specialty/OTC model and domestic Korean market positioning.
• Chong Kun Dang Pharmaceutical: Korean pharmaceutical company with specialty generics and branded Rx across multiple therapeutic areas. Comparable as a domestic Korean specialty/generics player with hospital-channel focus.
• Daewoong Pharmaceutical: Major Korean pharmaceutical company operating in specialty therapeutics, biosimilars, and OTC. Comparable on its specialty Rx plus biosimilars/OTC mix and Korean market focus.
• Dong-A ST: Korean specialty pharma with strong presence in oncology, urology, and consumer health brands. Comparable therapeutic footprint and similar hybrid Rx/OTC structure to Alvogen Korea.
• Yuhan Corporation: Major Korean pharmaceutical company with a diversified portfolio spanning specialty Rx, branded generics, and OTC/consumer health. Comparable to Alvogen Korea across its hybrid Rx/OTC model and domestic market focus.
• JW Pharmaceutical: Korean specialty generics and pharmaceutical company with focus areas overlapping Alvogen Korea's oncology and specialty portfolio. Comparable as a mid-sized Korean specialty generics player.
• Green Cross Corporation: Korean pharmaceutical company with specialty therapeutics, plasma products, and consumer health. Comparable on the hybrid specialty/OTC model serving Korean healthcare providers and consumers.
• Hanmi Pharmaceutical: One of South Korea's largest specialty pharmaceutical companies with a deep oncology, immunology, and specialty generics pipeline. Most directly comparable to Alvogen Korea on therapeutic focus (oncology/immunology) and Korean market presence, though at significantly larger scale.

Emerging players

• Celltrion: Korean biosimilars and specialty biologics leader. Partial overlap with Alvogen Korea's specialty/oncology focus, particularly relevant as a benchmark for biosimilar commercial strategy in Korea.

Broad incumbents

• Lotus Pharmaceutical: Parent company of Alvogen Korea; a broader specialty pharmaceutical group operating across Taiwan, Southeast Asia, China, Korea, and the US. Comparable as the umbrella entity whose pipeline and partnerships Alvogen Korea leverages.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@lotuspharma4085
• LinkedInlinkedin.com/company/alvogen-korea

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alvogen Korea